| 摘要 |
PURPOSE:To provide a plasma-derivative containing a clinically safe and well controlled plasma component. CONSTITUTION:The plasma derivative contains a plasma component substantially containing one kind of antigen selected from among a) type A sugar chain antigen and H (O) type sugar chain antigen, b) type B sugar chain antigen and H (O) type sugar chain antigen, c) type A sugar chain antigen, B type sugar chain antigen, and H (O) type sugar chain antigen, and H (O) type, and d) H (O) type sugar chain antigen as an effective component. In addition, the plasma derivative also contains a plasma component from which the A type and B type sugar chain antigens are removed as another effective component. Therefore, this plasma derivative is useful for the transfusion, etc., of a plasma- derived component at the time of treating patients suffering from hemophilia, vW disease, etc. |
